Filtered By:
Infectious Disease: Hepatitis C
Countries: Taiwan Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 157 results found since Jan 2013.
A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-na ïve chronic hepatitis C patients in Taiwan
Publication date: Available online 18 November 2016 Source:The Kaohsiung Journal of Medical Sciences Author(s): Pei-Chien Tsai, Ta-Wei Liu, Meng-Hsuan Hsieh, Ming-Lun Yeh, Po-Cheng Liang, Yi-Hung Lin, Ching-I Huang, Chung-Feng Huang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu Treatments with pegylated interferon/ribavirin (PEG-IFN/RBV) has been standard-of-care in patients with chronic hepatitis C virus (HCV) (CHC) infection and reimbursed in Taiwan. However, the actual cost-effectiveness remains unclear. We aimed to evaluate a real-world cost-effe...
Source: The Kaohsiung Journal of Medical Sciences - November 18, 2016 Category: Universities & Medical Training Source Type: research
A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
CONCLUSIONS: In conclusion, our results confirmed that insurance coverage of DAAs led to better clinical outcomes than INF, and this may reduce increases in medical expenses and the risks of rehospitalization and liver function disorders. What is known on this topic Interferon for hepatitis C have low efficacy with serious side effects, while the efficacy of new oral drugs (direct-acting antivirals, DAAs) is high. DAAs were approved for listing in Taiwan in December 2013, and they have been covered by National Health Insurance since January 2017. Little is known about DAA-related real-world evidence following the coverage ...
Source: Current Medical Research and Opinion - December 1, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
High prevalence of genotype 6 hepatitis C virus infection in Southern Taiwan using Abbott genotype assays
ConclusionsGT 6 is the major factor for high ambiguous rate by GT II. Unexpected high prevalence of GT 6 (18.3%) in Southern Taiwan, especially subtype 6 g, closely related to Indonesian strains, is first reported.
Source: Journal of the Formosan Medical Association - August 14, 2019 Category: General Medicine Source Type: research
High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan
In conclusion, the favorable IL-28B rs8099917 polymorphism occurs in high frequency in this multiracial area, which might be important to help guide physicians and patients in their future clinical decisions.
Source: The Kaohsiung Journal of Medical Sciences - July 2, 2017 Category: Universities & Medical Training Source Type: research
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients
Publication date: Available online 1 July 2017 Source:The Kaohsiung Journal of Medical Sciences Author(s): Ching-I Huang, Chung-Feng Huang, Ming-Lun Yeh, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Chia-Yen Dai, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) has recently been developed as a promising liver fibrosis glyco biomarker. We assessed its efficacy in evaluating liver disease severity in chronic hepatitis C (CHC) in Taiwan. The association between WFA+-M2BP and histological features was evaluate...
Source: The Kaohsiung Journal of Medical Sciences - July 2, 2017 Category: Universities & Medical Training Source Type: research
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
Conclusion Boceprevir plus peginterferon/ribavirin is effective in the treatment of HCV-1/HBV dually infected patients' refractory to prior peginterferon/ribavirin combination therapy.
Source: Journal of the Formosan Medical Association - July 9, 2017 Category: General Medicine Source Type: research
A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders
Conclusion For a naïve patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries.
Source: Journal of the Chinese Medical Association - June 2, 2018 Category: General Medicine Source Type: research
A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders
ConclusionFor a naïve patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries.
Source: Journal of the Chinese Medical Association - July 5, 2018 Category: General Medicine Source Type: research
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
ConclusionBoceprevir plus peginterferon/ribavirin is effective in the treatment of HCV-1/HBV dually infected patients' refractory to prior peginterferon/ribavirin combination therapy.
Source: Journal of the Formosan Medical Association - July 5, 2018 Category: General Medicine Source Type: research
A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders
ConclusionFor a naïve patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries.
Source: Journal of the Chinese Medical Association - July 10, 2018 Category: General Medicine Source Type: research
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
ConclusionBoceprevir plus peginterferon/ribavirin is effective in the treatment of HCV-1/HBV dually infected patients' refractory to prior peginterferon/ribavirin combination therapy.
Source: Journal of the Formosan Medical Association - July 10, 2018 Category: General Medicine Source Type: research
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
ConclusionsSOF/DCV with or without ribavirin is highly effective and safe for patients with genotype 2 HCV infection in real-world experience in Taiwan.
Source: Journal of the Formosan Medical Association - October 11, 2018 Category: General Medicine Source Type: research
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
ConclusionA minority of Taiwanese CHC patients were recommended PEG-IFN/RBV, of which few were willing to receive treatment.
Source: Journal of the Formosan Medical Association - November 17, 2018 Category: General Medicine Source Type: research
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
ConclusionInterferon-free GLE/PIB regimen is highly effective and safe for Asian chronic hepatitis C patients with advanced hepatic fibrosis or compensated cirrhosis.
Source: Journal of the Formosan Medical Association - July 4, 2019 Category: General Medicine Source Type: research
Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan
ConclusionCompared to the two-step process in community-based screening, continuous screening with the HCVcAg test as a one-step tool for active HCV infection was cost-effective in areas with low seroprevalence of HCV in Taiwan.
Source: Journal of the Formosan Medical Association - July 23, 2019 Category: General Medicine Source Type: research
